252 related articles for article (PubMed ID: 25963924)
1. Survival outcomes of secondary cancers in patients with Waldenström macroglobulinemia: An analysis of the SEER database.
Castillo JJ; Olszewski AJ; Kanan S; Meid K; Hunter ZR; Treon SP
Am J Hematol; 2015 Aug; 90(8):696-701. PubMed ID: 25963924
[TBL] [Abstract][Full Text] [Related]
2. Survival of patients newly diagnosed with colorectal cancer and with a history of previous cancer.
Pruitt SL; Gerber DE; Zhu H; Heitjan DF; Maddineni B; Xiong D; Singal AG; Tavakkoli A; Halm EA; Murphy CC
Cancer Med; 2021 Jul; 10(14):4752-4767. PubMed ID: 34190429
[TBL] [Abstract][Full Text] [Related]
3. Overall and cancer-specific survival of patients with breast, colon, kidney, and lung cancers with and without chronic lymphocytic leukemia: a SEER population-based study.
Solomon BM; Rabe KG; Slager SL; Brewer JD; Cerhan JR; Shanafelt TD
J Clin Oncol; 2013 Mar; 31(7):930-7. PubMed ID: 23341508
[TBL] [Abstract][Full Text] [Related]
4. Incidence of secondary malignancies among patients with Waldenström macroglobulinemia: An analysis of the SEER database.
Castillo JJ; Olszewski AJ; Hunter ZR; Kanan S; Meid K; Treon SP
Cancer; 2015 Jul; 121(13):2230-6. PubMed ID: 25757851
[TBL] [Abstract][Full Text] [Related]
5. Evidence of increasing mortality with longer diagnostic intervals for five common cancers: a cohort study in primary care.
Tørring ML; Frydenberg M; Hansen RP; Olesen F; Vedsted P
Eur J Cancer; 2013 Jun; 49(9):2187-98. PubMed ID: 23453935
[TBL] [Abstract][Full Text] [Related]
6. Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database.
Castillo JJ; Olszewski AJ; Kanan S; Meid K; Hunter ZR; Treon SP
Br J Haematol; 2015 Apr; 169(1):81-9. PubMed ID: 25521528
[TBL] [Abstract][Full Text] [Related]
7. Stage at diagnosis and early mortality from cancer in England.
McPhail S; Johnson S; Greenberg D; Peake M; Rous B
Br J Cancer; 2015 Mar; 112 Suppl 1(Suppl 1):S108-15. PubMed ID: 25734389
[TBL] [Abstract][Full Text] [Related]
8. Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: evidence from population-based and clinical cohorts.
Huang KP; Weinstock MA; Clarke CA; McMillan A; Hoppe RT; Kim YH
Arch Dermatol; 2007 Jan; 143(1):45-50. PubMed ID: 17224541
[TBL] [Abstract][Full Text] [Related]
9. Persistent socioeconomic inequalities in cancer survival in the United States: 1973-2007 surveillance, epidemiology and end results (SEER) data for breast cancer and non-Hodgkin's lymphoma.
Kato I; Booza J; Quarshie WO; Schwartz K
J Registry Manag; 2012; 39(4):158-66. PubMed ID: 23493021
[TBL] [Abstract][Full Text] [Related]
10. Non-small-cell lung cancer after breast cancer: a population-based study of clinicopathologic characteristics and survival outcomes in 3529 women.
Milano MT; Strawderman RL; Venigalla S; Ng K; Travis LB
J Thorac Oncol; 2014 Aug; 9(8):1081-90. PubMed ID: 25157761
[TBL] [Abstract][Full Text] [Related]
11. [Reference data on survival of cancer patients in 17 European countries].
Sant M
Epidemiol Prev; 2000; 24(1):44-5. PubMed ID: 10748550
[No Abstract] [Full Text] [Related]
12. Survival after second primary lung cancer: a population-based study of 187 Hodgkin lymphoma patients.
Milano MT; Li H; Constine LS; Travis LB
Cancer; 2011 Dec; 117(24):5538-47. PubMed ID: 21692074
[TBL] [Abstract][Full Text] [Related]
13. Non-melanoma skin cancer may be a marker of poor prognosis in patients with non-Hodgkin's lymphoma.
Hjalgrim H; Frisch M; Storm HH; Glimelius B; Pedersen JB; Melbye M
Int J Cancer; 2000 Mar; 85(5):639-42. PubMed ID: 10699942
[TBL] [Abstract][Full Text] [Related]
14. Second primary cancers in the Vaud and Neuchâtel Cancer Registries.
Levi F; Randimbison L; Rafael BM; Manuela MC; La Vecchia C
Eur J Cancer Prev; 2015 Mar; 24(2):150-4. PubMed ID: 25397586
[TBL] [Abstract][Full Text] [Related]
15. Screening for second malignancies in mycosis fungoides: non-Hodgkin lymphoma, Hodgkin lymphoma, lung cancer, bladder cancer and melanoma.
Goyal A; O'Leary D; Goyal K; Rubin N; Janakiram M
J Eur Acad Dermatol Venereol; 2021 Sep; 35(9):1821-1829. PubMed ID: 34013554
[TBL] [Abstract][Full Text] [Related]
16. Risk Factors for Melanoma Among Survivors of Non-Hodgkin Lymphoma.
Lam CJ; Curtis RE; Dores GM; Engels EA; Caporaso NE; Polliack A; Warren JL; Young HA; Levine PH; Elmi AF; Fraumeni JF; Tucker MA; Morton LM
J Clin Oncol; 2015 Oct; 33(28):3096-104. PubMed ID: 26240221
[TBL] [Abstract][Full Text] [Related]
17. Antihypertensive medications and survival in patients with cancer: a population-based retrospective cohort study.
Holmes S; Griffith EJ; Musto G; Minuk GY
Cancer Epidemiol; 2013 Dec; 37(6):881-5. PubMed ID: 24075077
[TBL] [Abstract][Full Text] [Related]
18. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System.
Barnholtz-Sloan JS; Sloan AE; Davis FG; Vigneau FD; Lai P; Sawaya RE
J Clin Oncol; 2004 Jul; 22(14):2865-72. PubMed ID: 15254054
[TBL] [Abstract][Full Text] [Related]
19. Cancer mortality surveillance--United States, 1990-2000.
Stewart SL; King JB; Thompson TD; Friedman C; Wingo PA
MMWR Surveill Summ; 2004 Jun; 53(3):1-108. PubMed ID: 15179359
[TBL] [Abstract][Full Text] [Related]
20. Neighborhood and Individual Socioeconomic Disadvantage and Survival Among Patients With Nonmetastatic Common Cancers.
Cheng E; Soulos PR; Irwin ML; Cespedes Feliciano EM; Presley CJ; Fuchs CS; Meyerhardt JA; Gross CP
JAMA Netw Open; 2021 Dec; 4(12):e2139593. PubMed ID: 34919133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
